Galera Therapeutics reports statistically significant results in a 223-patient phase IIb trial of GC4419 for oral mucositis in head and neck cancer

LSU Health New Orleans receives $3.1M grant to study head-and-neck cancer incidence in people living with HIV

LSU Health New Orleans was awarded a five-year, $3.1 million grant from the National Institute of Dental and Craniofacial Research.

November 15, 2024

Vol.50 No.43

Clinical

Randomized trial failed to accrue, but data point to preoperative chemo as viable option in sinonasal cancer

If clinical research were anything like fly fishing, the scientific question that EA3163 trial attempted to answer might be considered “the one that got away”.

SU2C announces grants supporting research in six cancer types

Stand Up To Cancer announced grants to several teams of leading cancer investigators in support of cutting-edge research in a variety of cancers including head and neck, pediatric, pancreatic, breast, rectal, and gastro-esophageal cancers, as well as research focused on how the microbiome communicates with the immune system.

October 18, 2024

Vol.50 No.39

Clinical Roundup

Keytruda meets primary endpoint as perioperative treatment regimen in resected, locally advanced HNSCC

The phase III KEYNOTE-689 trial evaluating Keytruda (pembrolizumab), Merck’s anti-PD-1 therapy, as a perioperative treatment for patients newly diagnosed with stage 3 or 4A, resected, locally advanced head and neck squamous cell carcinoma met its primary endpoint of event-free survival.

October 11, 2024

Vol.50 No.38

Clinical Roundup

Mayo Clinic performs world’s first known successful total larynx transplant in a patient with active cancer

A multidisciplinary team of doctors at Mayo Clinic in Arizona performed the third known total larynx transplant in the U.S.

July 12, 2024

Vol.50 No.28

Conversation with The Cancer Letter

Robert L. Ferris named executive director of UNC Lineberger—with an additional job as chief of oncology services

Robert L. Ferris, a head-and-neck surgeon and an expert in cancer immunotherapy was named the executive director of UNC Lineberger Comprehensive Cancer Center and the chief of oncology services at UNC Health.

June 21, 2024

Vol.50 No.25

By Paul Goldberg

Galera Therapeutics reports statistically significant results in a 223-patient phase IIb trial of GC4419 for oral mucositis in head and neck cancer

YOU MAY BE INTERESTED IN

LSU Health New Orleans receives $3.1M grant to study head-and-neck cancer incidence in people living with HIV

Randomized trial failed to accrue, but data point to preoperative chemo as viable option in sinonasal cancer

SU2C announces grants supporting research in six cancer types

Keytruda meets primary endpoint as perioperative treatment regimen in resected, locally advanced HNSCC

Mayo Clinic performs world’s first known successful total larynx transplant in a patient with active cancer

Robert L. Ferris named executive director of UNC Lineberger—with an additional job as chief of oncology services

Renew today!

Subscriber content

Never miss an issue!

Login